VAGUS NERVE STIMULATION REIMBURSEMENT
HB 257 mandates insurance reimbursement for vagus nerve stimulation therapy in New Mexico, expanding access to this FDA-approved treatment for epilepsy and certain psychiatric conditions.
HB 257 mandates insurance reimbursement for vagus nerve stimulation therapy in New Mexico, expanding access to this FDA-approved treatment for epilepsy and certain psychiatric conditions.
HB 257 would require New Mexico health insurance plans to cover vagus nerve stimulation (VNS) therapy as a treatment option. The bill mandates reimbursement for this medical procedure, which involves implanting a device that sends electrical impulses to the vagus nerve to treat conditions like epilepsy, depression, and chronic pain. The measure has passed committee review and is advancing through the legislative process.
Vagus nerve stimulation is an FDA-approved treatment for several conditions, but insurance coverage varies significantly, creating access barriers for patients who might benefit. Requiring reimbursement could expand treatment options for individuals with treatment-resistant epilepsy and certain mood disorders, particularly those without resources to self-pay. However, this also represents a significant mandate on insurers that could affect premium costs and coverage decisions.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.